Retatrutide vs Tirzepatide

Side-by-side comparison of Retatrutide, Tirzepatide — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Retatrutide Retatrutide (GIP/GLP-1/Glucagon Triple Agonist) Weight Loss Tirzepatide Tirzepatide (GIP/GLP-1 Dual Agonist) Weight Loss
Basics
Molecular type Triple GIP/GLP-1/Glucagon Receptor AgonistDual GIP/GLP-1 Receptor Agonist
Amino acids —39
Molecular weight —4,813.5 Da
Half-life ~6 days~5 days
Route(s) Subcutaneous injectionSubcutaneous injection
Mechanism & Research
Primary mechanism Retatrutide activates three incretin and metabolic hormone receptors simultaneously. GLP-1 receptor agonism drives appetite suppression, slows gastric emptying, and reduces food intake — the primary mechanism shared with… Tirzepatide's dual mechanism differentiates it from pure GLP-1 agonists. The GIP component contributes additional appetite suppression via hypothalamic GIP receptors and improves insulin secretion efficiency. The two inc…
Research status Phase 3 Trial FDA Approved
Evidence summary Retatrutide is in Phase 3 clinical trials (NCT06052826) as of 2026, following highly positive Phase 2 data. The Phase 2 trial (NCT04881760, n=338) is the strongest weight loss signal from any pharmacological agent in hum… Tirzepatide's clinical development programme (SURPASS for diabetes, SURMOUNT for obesity) has consistently demonstrated superior weight loss outcomes to comparator GLP-1 agonists. The SURMOUNT-1 trial set a new benchmark…
Protocol & Dosing
Typical dose 2mg → 12mg weekly (titration)2.5mg → 15mg weekly
Frequency Once weeklyOnce weekly
Duration Ongoing (Phase 3)Ongoing (chronic)
Timing Same day each weekSame day each week, any time of day
Safety
Common side effects
  • Nausea
  • Vomiting
  • Diarrhoea
  • Constipation
  • Nausea (33–40%)
  • Diarrhoea (17–22%)
  • Vomiting (11–13%)
  • Constipation (11–12%)
Contraindications
  • History of MEN2 or medullary thyroid carcinoma
  • Active pancreatitis
  • Pregnancy
  • Personal/family history of MEN2 or medullary thyroid carcinoma
  • Known GIP or GLP-1 receptor agonist hypersensitivity
  • Severe renal impairment (caution)
Anti-doping Not Prohibited Not Prohibited
Deeper reading
Related peptides Tirzepatide, Semaglutide, AOD-9604 Semaglutide, AOD-9604, Tesamorelin
Full profile Read full Retatrutide profile → Read full Tirzepatide profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.